John P. Northcott's most recent trade in Nektar Therapeutics was a trade of 4,592 Common Stock done at an average price of $3.9 . Disclosure was reported to the exchange on May 16, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 16 May 2022 | 4,592 | 223,210 (0%) | 0% | 3.9 | 18,138 | Common Stock |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 16 Feb 2022 | 4,852 | 227,802 (0%) | 0% | 10.9 | 53,129 | Common Stock |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 67,150 | 67,150 | - | - | Stock Option | |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 37,800 | 232,654 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 16 Nov 2021 | 6,061 | 194,854 (0%) | 0% | 13.2 | 79,763 | Common Stock |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 16 Aug 2021 | 6,192 | 200,915 (0%) | 0% | 13.8 | 85,635 | Common Stock |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 17 May 2021 | 6,085 | 207,107 (0%) | 0% | 18.3 | 111,356 | Common Stock |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.37 per share. | 16 Feb 2021 | 15,358 | 213,192 (0%) | 0% | 22.4 | 343,558 | Common Stock |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 51,000 | 51,000 | - | - | Stock Option | |
| Nektar Therapeutics | John P. Northcott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 28,550 | 228,550 (0%) | 0% | 0 | Common Stock |